|
RAB2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6251444634463E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.51656465163796E-12 |
| Normal-vs-Stage2 |
3.46330000233763E-08 |
| Normal-vs-Stage3 |
6.3504757008559E-14 |
| Normal-vs-Stage4 |
1.05609965217468E-11 |
| Stage1-vs-Stage2 |
4.308200E-01 |
| Stage1-vs-Stage3 |
7.479700E-03 |
| Stage1-vs-Stage4 |
2.433600E-02 |
| Stage2-vs-Stage3 |
2.939200E-01 |
| Stage2-vs-Stage4 |
2.679800E-01 |
| Stage3-vs-Stage4 |
8.771000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.7715611723761E-16 |
| Normal-vs-AfricanAmerican |
2.796400E-04 |
| Normal-vs-Asian |
1.93900000000635E-06 |
| Caucasian-vs-AfricanAmerican |
2.017200E-01 |
| Caucasian-vs-Asian |
1.140820E-01 |
| AfricanAmerican-vs-Asian |
9.345400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.05484543111834E-13 |
| Normal-vs-Female |
1.63624669369256E-12 |
| Male-vs-Female |
5.273200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.56870122131659E-11 |
| Normal-vs-Age(41-60Yrs) |
3.37285754881123E-13 |
| Normal-vs-Age(61-80Yrs) |
1.65956137720968E-12 |
| Normal-vs-Age(81-100Yrs) |
2.426500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.020040E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.197600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.682400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.960380E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.998800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.585600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.002000E-04 |
| Classical-VS-Follicular |
2.019000E-01 |
| Classical-VS-Other |
6.474400E-01 |
| Classical-VS-Normal |
6.75879996414608E-09 |
| Tall-VS-Follicular |
2.170200E-02 |
| Tall-VS-Other |
1.717170E-01 |
| Tall-VS-Normal |
1.67055258515347E-12 |
| Follicular-VS-Other |
9.731600E-01 |
| Follicular-VS-Normal |
2.19670004408812E-09 |
| Other-VS-Normal |
5.343000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.91748872125208E-14 |
| Normal-vs-N1 |
1.17309999492221E-08 |
| N0-vs-N1 |
8.294400E-01 |
|
|
